References
- Alley MC, Hollingshead MG, Dykes DJ, Waud WR. (2004). Human tumor xenograft models in NCI drug development. In: Teicher BA, Andrews PA, eds. Anticancer drug development guide: preclinical screening, clinical trials, and approval. 2nd ed. Totowa (NJ): Humana Press, Inc., 125–52
- Bailon P, Palleroni A, Schaffer CA, et al. (2001). Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12:195–202
- Basch E, Gabardi S, Ulbricht C. (2003). Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 60:356–9
- Bian X, Shen F, Chen Y, et al. (2010). PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential. Biotechnol Lett 32:883–90
- Clark R, Olson K, Fuh G, et al. (1996). Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271:21969–77
- He XH, Shaw PC, Tam SC. (1999). Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci 65:355–68
- Kaur I, Yadav SK, Hariprasad G, et al. (2012). Balsamin, a novel ribosome-inactivating protein from the seeds of Balsam apple Momordica balsamina. Amino Acids 43:973–81
- Leung KC, Meng ZQ, Ho WK. (1997). Antigenic determination fragments of alpha-momorcharin. Biochim Biophys Acta 1336:419–24
- Li M, Chen Y, Liu Z, et al. (2009). Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophys Sin (Shanghai) 41:792–9
- Meng Y, Liu B, Lei N, et al. (2012). Alpha-momorcharin possessing high immunogenicity, immunotoxicity and hepatotoxicity in SD rats. J Ethnopharmacol 139:590–8
- Ng TB, Liu WK, Sze SF, Yeung HW. (1994). Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen Pharmacol 25:75–7
- Niv-Spector L, Shpilman M, Boisclair Y, Gertler A. (2012). Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist. Protein Expr Purif 81:186–92
- Park SW, Lawrence CB, Linden JC, Vivanco JM. (2002). Isolation and characterization of a novel ribosome-inactivating protein from root cultures of pokeweed and its mechanism of secretion from roots. Plant Physiol 130:164–78
- Park SW, Prithiviraj B, Vepachedu R, Vivanco JM. (2006). Isolation and purification of ribosome-inactivating proteins. Methods Mol Biol 318:335–47
- Wang YX, Jacob J, Wingfield PT, et al. (2000). Anti-HIV and anti-tumor protein MAP30, a 30 kDa single-strand type-I RIP, shares similar secondary structure and beta-sheet topology with the A chain of ricin, a type-II RIP. Protein Sci 9:138–44
- Wang JH, Tam SC, Huang H, et al. (2004). Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro. Biochem Biophys Res Commun 317:965–71
- Zheng JC, Lei N, He QC, et al. (2012). PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of alpha-momorcharin in vivo. Immunopharmacol Immunotoxicol 34:866–73
- Zhu G, Huang Q, Qian M, Tang Y. (2001). Crystal structure of alpha-momorcharin in 80% acetonitrile–water mixture. Biochim Biophys Acta 1548:152–8